Business Description
Bellicum Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0794811077
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -3.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -130.6 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -68.2 | |||||
3-Year EBITDA Growth Rate | 65.5 | |||||
3-Year EPS without NRI Growth Rate | 64.9 | |||||
3-Year FCF Growth Rate | 63.1 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 77.88 | |||||
9-Day RSI | 62.85 | |||||
14-Day RSI | 52.73 | |||||
6-1 Month Momentum % | -73.47 | |||||
12-1 Month Momentum % | -79.8 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.04 | |||||
Quick Ratio | 3.04 | |||||
Cash Ratio | 2.63 | |||||
Days Sales Outstanding | 82.54 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.8 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1579.97 | |||||
Net Margin % | -1483.95 | |||||
FCF Margin % | -1506.99 | |||||
ROA % | -127.22 | |||||
ROIC % | -2891.5 | |||||
ROC (Joel Greenblatt) % | -133853.93 | |||||
ROCE % | -175.23 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.56 | |||||
EV-to-EBIT | 1.91 | |||||
EV-to-EBITDA | 1.91 | |||||
EV-to-Revenue | -30.13 | |||||
EV-to-FCF | 1.99 | |||||
Earnings Yield (Greenblatt) % | 52.36 | |||||
FCF Yield % | -3148.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Bellicum Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.416 | ||
EPS (TTM) (€) | -0.673 | ||
Beta | 0 | ||
Volatility % | 233.86 | ||
14-Day RSI | 52.73 | ||
14-Day ATR (€) | 0.016801 | ||
20-Day SMA (€) | 0.124025 | ||
12-1 Month Momentum % | -79.8 | ||
52-Week Range (€) | 0.072 - 1.33 | ||
Shares Outstanding (Mil) | 9.5 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bellicum Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bellicum Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Bellicum Pharmaceuticals Inc Frequently Asked Questions
What is Bellicum Pharmaceuticals Inc(FRA:BPXA)'s stock price today?
When is next earnings date of Bellicum Pharmaceuticals Inc(FRA:BPXA)?
Does Bellicum Pharmaceuticals Inc(FRA:BPXA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |